Search

everythinglearnresearchcommunity

for

Search:↓

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

A user experiencing significant hair loss started using Dutasteride, a drug typically used for prostate issues, and noticed a positive change in hair thickness and volume after 5 months. Other users in the conversation also shared their experiences and observations with Dutasteride, with one mentioning additional use of oral Minoxidil.

The potential accuracy and trustworthiness of websites selling Pyrilutamide, a drug related to hair loss treatments such as Minoxidil, Finasteride, and RU58841; and whether Pyrilutamide is four times stronger than RU58841.

User tried various hair loss treatments with side effects. Seeks advice on hair transplant without maintenance drug.

A user humorously shared that someone at their high school gave out finasteride pills, which introduced them to the drug for their receding hairline. The conversation also touched on the high school's location and appearance, with some users joking about their own hair loss and treatments like minoxidil and finasteride.

Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.

Dutasteride may cause mental fog, vision blurriness, and sleep issues. Users suggest trying topical versions of the drug to mitigate side effects.

A user is concerned about the impact of topical dutasteride on sperm quality and potential long-term fertility issues. They are using microneedling with a 0.025% dutasteride solution and are seeking information on whether sperm parameters return to normal after stopping the drug.

Some people claim Dutasteride worsened their hair loss, causing concern among users. Reasons suggested include initial shedding phases, incorrect attribution to Dutasteride when other factors are involved, genetic variations affecting drug response, and the possibility of non-authentic medication.

The conversation discusses whether using pyrilutamide would interfere with minoxidil's ability to regrow hair, considering pyrilutamide is seen as a maintenance drug that stops shedding, while minoxidil promotes hair growth but causes initial shedding.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

The conversation is about differing experiences with finasteride for hair loss, with some users reporting side effects and others not, and the debate over the drug's safety and effectiveness. Specific treatments mentioned include finasteride, dutasteride, and topical finasteride.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The user's 42 month experience using finasteride for hair loss, their opinion on minoxidil use and the potential of pyrilutamide and another Chinese drug as treatments.

The potential of verteporfin to heal wounds without scarring; however, despite its promising preclinical trials and coverage from a major media outlet, there is still no official clinical trial result and the drug has only garnered attention from hair loss communities.

Finasteride, a medication for hair loss that has both positive and negative effects. Users discussed their own personal experiences with the drug as well as potential side-effects of taking it, such as erectile dysfunction or gynecomastia. Suggestions were also made about starting at a lower dosage to minimize these risks.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.

A user beginning to take Pyrilutamide as a treatment for their hair loss, and other users sharing their experiences with the drug or similar treatments such as Minoxidil, Finasteride, and RU58841.

This conversation was about a user's progress pictures from using minoxidil and microneedling to treat hair loss. Other users suggested finasteride as an additional treatment, while cautioning that the drug could have permanent side effects.

The conversation discusses skepticism about the effectiveness of new hair loss treatments, mentioning that despite 40 years of research, only accidental discoveries like Minoxidil and Finasteride have been made. It also notes that drug development is a slow process, often taking a decade or more to bring a new drug to market.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

User experienced side effects from topical finasteride, including penile pain and reduced sexual satisfaction, and is unsure whether to resume or avoid the treatment. They are seeking advice on whether tapering off the drug might help.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.

A female user's experience using Spironolactone to treat Female Pattern Hair Loss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.